Partnerships
Partnerships
Cybin x Kernel: A New Frontier in
Psychedelic Therapeutics
About the Partnership
Cybin is leveraging Kernel Flow® to quantify brain activity during psychedelic experiences in real time, adding an exciting dimension to Cybin’s investigative work focused on developing breakthrough psychedelic-based therapeutics for mental health conditions and substance-use disorders.
About Kernel Flow
Kernel Flow is a wearable headset that measures brain activity by recording local changes in blood oxygenation. It is safe, adjustable, and can accommodate nearly anyone.
Kernel Flow is a groundbreaking neurotechnology that reduces loud, expensive, and room-sized equipment to a head-worn apparatus while providing neural activity data of the highest possible optical quality. This combination has never existed in such a commercial and scalable device, all factors for why brain interfaces and neuroimaging technology has largely remained in academic labs or hospital basements and why mental health diagnosis and treatment have behavioral, instead of biomarker, endpoints.
The entire system is the size and look of a bicycle helmet and could, in the future, be more broadly used for neuroscientific or physiological studies of brain activity during psychedelic use.
About Kernel Flow
Kernel Flow is a wearable headset that measures brain activity by recording local changes in blood oxygenation. It is safe, adjustable, and can accommodate nearly anyone.
Kernel Flow is a groundbreaking neurotechnology that reduces loud, expensive, and room-sized equipment to a head-worn apparatus while providing neural activity data of the highest possible optical quality. This combination has never existed in such a commercial and scalable device, all factors for why brain interfaces and neuroimaging technology has largely remained in academic labs or hospital basements and why mental health diagnosis and treatment have behavioral, instead of biomarker, endpoints.
The entire system is the size and look of a bicycle helmet and could, in the future, be more broadly used for neuroscientific or physiological studies of brain activity during psychedelic use.
For more information on the Kernel Feasibility Study, please click here
Clinilabs
Cybin has partnered with Clinilabs Drug Development Corporation, a global, full-service contract research organization with deep expertise in central nervous system drug development, to carry out the Phase 1/2a clinical trial evaluating CYB003for the treatment of major depressive disorder.
University of Washington
Cybin has formed a strategic collaboration with the University of Washington and is co-sponsoring a trial that aims to treat symptoms of depression, anxiety, burnout and post-traumatic stress among frontline doctors, nurses and healthcare professionals through psychedelic therapeutics.
The trial will be led by Dr. Anthony Back and be hosted in Seattle, a city hard hit by an early coronavirus outbreak.
Greenbrook TMS
Cybin and Greenbrook are both on a mission to assist individuals suffering from depression and the synergistic opportunity to combine forces was evident. Cybin and Greenbrook will work together to establish Mental Health Centers of Excellence for the purpose of facilitating research and development of innovative psychedelic compound-based therapeutics for patients suffering from depression. The network of outpatient mental health service centers that Greenbrook has built over the years will provide Cybin a leading market advantage to resources and patients that can assist in accelerating clinical study programs in the US as patient access regularly becomes a hurdle in this specific process.
